

Contents

1	Zona Glomerulosa of the Adrenal Cortex: Source of Aldosterone	1
2	Pathway of Aldosterone Biosynthesis	5
2.1	Classical Pathway and Alternative Pathways	5
2.2	Corticosterone as an Intermediate Product	6
2.3	18-Hydroxycorticosterone: Intermediate Product or By-product?	8
2.4	Alternative Pathway Through 18-Hydroxy-11-deoxycorticosterone? . . .	12
2.5	Deoxycorticosterone Secretion	14
3	Aldosterone Biosynthesis by Cell-Free Systems	16
4	Substances Directly Influencing Aldosterone Biosynthesis in Short-term Incubation or Perfusion Experiments	22
4.1	Angiotensins	22
4.1.1	Angiotensin II	22
4.1.2	Angiotensin III	27
4.1.3	Angiotensin I and Des-asp ¹ -angiotensin I	30
4.1.4	Synthetic Angiotensin Analogues	30
4.1.5	Adrenocortical Angiotensin Receptors	32
4.2	Monovalent Cations	34
4.2.1	Sodium	34
4.2.2	Potassium	37
4.2.3	Ammonium, Rubidium, and Cesium	41
4.2.4	Lithium	43
4.2.5	Hydrogen Ions	43
4.3	Divalent Cations	44
4.3.1	Calcium	44
4.3.2	Substances Affecting Transport and Second-Messenger Functions of Calcium	46
4.3.3	Magnesium	49
4.4	ACTH, ACTH-related Peptides, and Other Pituitary Hormones	49
4.4.1	ACTH	49
4.4.2	ACTH-related Pituitary Peptides	53
4.4.3	Prolactin	57

4.4.4	Aldosterone-Stimulating Factor	57
4.4.5	Vasopressin	58
4.5	Amines	59
4.5.1	Serotonin	59
4.5.2	Serotonin-Related Indole Derivatives	62
4.5.3	Serotonin Antagonists	63
4.5.4	Dopamine, Dopaminergic Agonists, and Dopamine Antagonists	64
4.5.5	Histamine and Histamine Antagonists	67
4.5.6	Adrenergic Agonists and Antagonists	67
4.6	Prostaglandins and Inhibitors of Prostaglandin Biosynthesis	68
4.6.1	Prostaglandins	68
4.6.2	Inhibitors of Prostaglandin Biosynthesis	70
4.7	Aldosterone-Inhibiting Peptides	71
4.7.1	Atrial Natriuretic Peptides	71
4.7.2	Adrenal-Medullary Inhibitory Factor	75
4.7.3	Somatostatin	75
4.8	Specific Inhibitors of Steroidogenic Enzymes	76
4.8.1	Metirapone	76
4.8.2	Su-8000, Su-9055, and Su-10603	77
4.8.3	Aminogluthethimide	79
4.8.4	Cyanosteroids	79
4.8.5	Spirolactones	80
4.9	Inhibitors of RNA or Protein Synthesis	81
4.9.1	Actinomycin D	81
4.9.2	Cycloheximide	82
4.9.3	Puromycin and Chloramphenicol	84
4.10	Steroid Hormones	85
4.10.1	Corticosteroids and Gestagens	85
4.10.2	Androgens and Estrogens	86
4.11	Ouabain	87
4.12	Miscellaneous Biological Substances with Direct Stimulatory or Inhibitory Effects on Aldosterone Biosynthesis	89
4.13	Site of Action of Stimulators or Inhibitors in the Biosynthetic Pathway	90
4.13.1	"Early Steps" and "Late Steps"	90
4.13.2	Endogenous Steroid Output	91
4.13.3	Conversion of Labeled Precursors	92
4.13.4	Experiments with Unlabeled Precursors	94
4.13.5	Experiments with Inhibitors of Steroidogenic Enzymes	95
4.14	Primary Effects and Intracellular Mediation	96
4.14.1	General Considerations	96
4.14.2	Cyclic AMP	97
4.14.3	Cyclic GMP	100

4.14.4	Calcium	101
4.14.5	Phospholipid Metabolism	104
4.14.6	Intracellular Potassium and (Na, K)-ATPase	106
5	Alterations in Aldosterone Biosynthesis and Secretion in Long-Term Experiments and Diseases	108
5.1	Alterations in Sodium Intake or in Sodium Balance	108
5.1.1	“Sodium Deficiency”	108
5.1.2	Morphological and Histochemical Changes	109
5.1.3	Altered Sensitivity of the Zona Glomerulosa to Aldosterone-Stimulating Substances	110
5.1.4	Sites of Action in the Biosynthetic Pathway	112
5.1.5	Role of the Renin-Angiotensin System	117
5.1.6	Role of Plasma Potassium Concentration	120
5.1.7	Role of Plasma Volume	120
5.1.8	Role of Plasma Sodium Concentration	124
5.1.9	Involvement of the Central Nervous System	125
5.2	Alterations in Potassium Intake or in Potassium Balance	126
5.2.1	General Considerations	126
5.2.2	Morphological Changes	127
5.2.3	Duration of Stimulatory Effects of Potassium	127
5.2.4	Alterations in Zona Glomerulosa Sensitivity	128
5.2.5	Site of Action in the Biosynthetic Pathway	129
5.2.6	Potassium-Induced Mitochondrial Protein	133
5.2.7	Potassium Intake and the Renin-Angiotensin System	133
5.3	Exogenous Angiotensin or Renin	136
5.3.1	Aldosterone Stimulation by Pressor and Nonpressor Doses	137
5.3.2	Selectivity of Aldosterone Stimulation	138
5.3.3	Persistence of Aldosterone Stimulation	140
5.3.4	Effects on Angiotensin II Receptors and on Steroidogenic Enzymes	142
5.3.5	Effects on Sodium Balance	143
5.3.6	Renal Arterial Infusion of Angiotensin II	144
5.3.7	Immunization Against Renin or Angiotensin	144
5.3.8	Morphological and Histochemical Alterations of the Adrenal Cortex	145
5.4	Pharmacological Blockade of the Renin-Angiotensin System	146
5.4.1	Angiotensin Antagonists	146
5.4.2	Converting-Enzyme Inhibitors	148
5.4.3	Beta-Adrenergic Blocking Agents	153
5.4.4	Inhibitors of Prostaglandin Synthesis	155
5.5	Role of the Kidneys	157
5.5.1	Renovascular Hypertension	157
5.5.2	Renal Denervation, Kidney Transplantation, and Unilateral Nephrectomy	163

5.5.3	Renal Failure and Hemodialysis	164
5.5.4	Bilateral Nephrectomy	166
5.5.5	Primary Reninism	173
5.5.6	Hyporeninemic Hypoaldosteronism	174
5.6	Role of the Pituitary Gland	175
5.6.1	Hypophysectomy and Hypopituitarism	176
5.6.2	Adrenocorticotropin (ACTH)	181
5.6.3	ACTH-Related Pituitary Peptides	190
5.6.4	Glucocorticoids	191
5.6.5	Growth Hormone	194
5.6.6	Prolactin	196
5.6.7	Thyroid Hormones	197
5.6.8	Vasopressin	198
5.7	Dopaminergic Regulation of Aldosterone Secretion	200
5.7.1	General Considerations	200
5.7.2	Experiments with Metoclopramide	201
5.7.3	Other Dopamine Antagonists	205
5.7.4	Dopamine and L-Dopa	206
5.7.5	Bromocriptine	208
5.8	Role of the Central Nervous System	210
5.8.1	General Considerations	210
5.8.2	Electrical and Humoral Stimulation of the Central Nervous System	210
5.8.3	Brain Lesions	212
5.8.4	Hypothalamic Factors	213
5.8.5	Pineal Gland	214
5.8.6	Spinal Cord Transection	215
5.8.7	Manic-depressive Psychosis	216
5.9	Normal Life	216
5.9.1	Fetal Development	216
5.9.2	Infancy and Childhood	219
5.9.3	Age	220
5.9.4	Diurnal Rhythms	221
5.9.5	Posture	224
5.9.6	Exercise	225
5.9.7	Heat and Cold	226
5.9.8	Altitude	228
5.9.9	Fasting and Refeeding	229
5.10	Estrogens and Progestogens	230
5.10.1	Exogenous Estrogens	230
5.10.2	Exogenous Progestogens	231
5.10.3	Oral Contraceptive Medication	233
5.10.4	Menstrual Cycle	235
5.10.5	Pregnancy	236

5.11	Aspects of Negative Feedback Regulation	241
5.11.1	Mineralocorticoids	241
5.11.2	Licorice and Carbenoxolone	245
5.11.3	Pseudohyperaldosteronism (Liddle's Syndrome)	245
5.11.4	Acquired Forms of Primary Hypoaldosteronism	246
5.11.5	Congenital Deficiencies of Steroidogenic Enzymes	247
5.11.6	Pseudohypoaldosteronism	252
5.11.7	Spirolactones	253
5.11.8	Heparin and Heparinoids	256
6	Conclusions	259
6.1	Multiplicity of Aldosterone-Stimulating Substances	259
6.2	"Adrenoglomerulotropins"	261
6.3	Physiological Inhibitors of Aldosterone Biosynthesis	262
6.4	The Shrinking Black Box	263
6.5	Long-Term Regulation of Late Steps in Aldosterone Biosynthesis	265
6.6	A Matter of Time	267
6.7	Enzymology of the Final Steps in Aldosterone Biosynthesis	269
6.8	Predominance of the Renin-Angiotensin System in the Physiological Control of Aldosterone Secretion?	272
6.9	Multifactorial Control of Aldosterone Biosynthesis	274
	References	277
	Subject Index	357